Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations

Panagiotis Baliakas; Andreas Agathangelidis; Anastasia Hadzidimitriou; Lesley Ann Sutton; Eva Minga; Athina Tsanousa; Lydia Scarfò; Zadie Davis; Xiao Jie Yan; Tait Shanafelt; Karla Plevova; Yorick Sandberg; Fie Juhl Vojdeman; Myriam Boudjogra; Tatiana Tzenou; Maria Chatzouli; Charles C. Chu; Silvio Veronese; Anne Gardiner; Larry Mansouri; Karin E. Smedby; Lone Bredo Pedersen; Denis Moreno; Kirsten Van Lom; Véronique Giudicelli; Hana Skuhrova Francova; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Lefteris Angelis; Achilles Anagnostopoulos; Marie Paule Lefranc; Monica Facco; Livio Trentin; Mark Catherwood; Marco Montillo; Christian H. Geisler; Anton W. Langerak; Sarka Pospisilova; Nicholas Chiorazzi; David Oscier; Diane F. Jelinek; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos

doi:10.1182/blood-2014-09-600874

Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations

Panagiotis Baliakas, Andreas Agathangelidis, Anastasia Hadzidimitriou, Lesley Ann Sutton, Eva Minga, Athina Tsanousa, Lydia Scarfò, Zadie Davis, Xiao Jie Yan, Tait Shanafelt, Karla Plevova, Yorick Sandberg, Fie Juhl Vojdeman, Myriam Boudjogra, Tatiana Tzenou, Maria Chatzouli, Charles C. Chu, Silvio Veronese, Anne Gardiner, Larry MansouriKarin E. Smedby, Lone Bredo Pedersen, Denis Moreno, Kirsten Van Lom, Véronique Giudicelli, Hana Skuhrova Francova, Florence Nguyen-Khac, Panagiotis Panagiotidis, Gunnar Juliusson, Lefteris Angelis, Achilles Anagnostopoulos, Marie Paule Lefranc, Monica Facco, Livio Trentin, Mark Catherwood, Marco Montillo, Christian H. Geisler, Anton W. Langerak, Sarka Pospisilova, Nicholas Chiorazzi, David Oscier, Diane F. Jelinek, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Paolo Ghia, Richard Rosenquist, Kostas Stamatopoulos

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Abstract

An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.

Original language	English (US)
Pages (from-to)	856-859
Number of pages	4
Journal	Blood
Volume	125
Issue number	5
DOIs	https://doi.org/10.1182/blood-2014-09-600874
State	Published - Jan 29 2015

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2014-09-600874

Cite this

Baliakas, P., Agathangelidis, A., Hadzidimitriou, A., Sutton, L. A., Minga, E., Tsanousa, A., Scarfò, L., Davis, Z., Yan, X. J., Shanafelt, T., Plevova, K., Sandberg, Y., Vojdeman, F. J., Boudjogra, M., Tzenou, T., Chatzouli, M., Chu, C. C., Veronese, S., Gardiner, A., ... Stamatopoulos, K. (2015). Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations. Blood, 125(5), 856-859. https://doi.org/10.1182/blood-2014-09-600874

Baliakas, P, Agathangelidis, A, Hadzidimitriou, A, Sutton, LA, Minga, E, Tsanousa, A, Scarfò, L, Davis, Z, Yan, XJ, Shanafelt, T, Plevova, K, Sandberg, Y, Vojdeman, FJ, Boudjogra, M, Tzenou, T, Chatzouli, M, Chu, CC, Veronese, S, Gardiner, A, Mansouri, L, Smedby, KE, Pedersen, LB, Moreno, D, Van Lom, K, Giudicelli, V, Francova, HS, Nguyen-Khac, F, Panagiotidis, P, Juliusson, G, Angelis, L, Anagnostopoulos, A, Lefranc, MP, Facco, M, Trentin, L, Catherwood, M, Montillo, M, Geisler, CH, Langerak, AW, Pospisilova, S, Chiorazzi, N, Oscier, D, Jelinek, DF, Darzentas, N, Belessi, C, Davi, F, Ghia, P, Rosenquist, R & Stamatopoulos, K 2015, 'Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations', Blood, vol. 125, no. 5, pp. 856-859. https://doi.org/10.1182/blood-2014-09-600874

@article{0b201ab8fde84ba4b353d5aee8b0c81d,

title = "Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations",

abstract = "An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.",

author = "Panagiotis Baliakas and Andreas Agathangelidis and Anastasia Hadzidimitriou and Sutton, {Lesley Ann} and Eva Minga and Athina Tsanousa and Lydia Scarf{\`o} and Zadie Davis and Yan, {Xiao Jie} and Tait Shanafelt and Karla Plevova and Yorick Sandberg and Vojdeman, {Fie Juhl} and Myriam Boudjogra and Tatiana Tzenou and Maria Chatzouli and Chu, {Charles C.} and Silvio Veronese and Anne Gardiner and Larry Mansouri and Smedby, {Karin E.} and Pedersen, {Lone Bredo} and Denis Moreno and {Van Lom}, Kirsten and V{\'e}ronique Giudicelli and Francova, {Hana Skuhrova} and Florence Nguyen-Khac and Panagiotis Panagiotidis and Gunnar Juliusson and Lefteris Angelis and Achilles Anagnostopoulos and Lefranc, {Marie Paule} and Monica Facco and Livio Trentin and Mark Catherwood and Marco Montillo and Geisler, {Christian H.} and Langerak, {Anton W.} and Sarka Pospisilova and Nicholas Chiorazzi and David Oscier and Jelinek, {Diane F.} and Nikos Darzentas and Chrysoula Belessi and Frederic Davi and Paolo Ghia and Richard Rosenquist and Kostas Stamatopoulos",

note = "Publisher Copyright: {\textcopyright} 2015 by The American Society of Hematology 10.1182/blood-2014-09-600874.",

year = "2015",

month = jan,

day = "29",

doi = "10.1182/blood-2014-09-600874",

language = "English (US)",

volume = "125",

pages = "856--859",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "5",

}

TY - JOUR

T1 - Not all IGHV3-21 chronic lymphocytic leukemias are equal

T2 - Prognostic considerations

AU - Baliakas, Panagiotis

AU - Agathangelidis, Andreas

AU - Hadzidimitriou, Anastasia

AU - Sutton, Lesley Ann

AU - Minga, Eva

AU - Tsanousa, Athina

AU - Scarfò, Lydia

AU - Davis, Zadie

AU - Yan, Xiao Jie

AU - Shanafelt, Tait

AU - Plevova, Karla

AU - Sandberg, Yorick

AU - Vojdeman, Fie Juhl

AU - Boudjogra, Myriam

AU - Tzenou, Tatiana

AU - Chatzouli, Maria

AU - Chu, Charles C.

AU - Veronese, Silvio

AU - Gardiner, Anne

AU - Mansouri, Larry

AU - Smedby, Karin E.

AU - Pedersen, Lone Bredo

AU - Moreno, Denis

AU - Van Lom, Kirsten

AU - Giudicelli, Véronique

AU - Francova, Hana Skuhrova

AU - Nguyen-Khac, Florence

AU - Panagiotidis, Panagiotis

AU - Juliusson, Gunnar

AU - Angelis, Lefteris

AU - Anagnostopoulos, Achilles

AU - Lefranc, Marie Paule

AU - Facco, Monica

AU - Trentin, Livio

AU - Catherwood, Mark

AU - Montillo, Marco

AU - Geisler, Christian H.

AU - Langerak, Anton W.

AU - Pospisilova, Sarka

AU - Chiorazzi, Nicholas

AU - Oscier, David

AU - Jelinek, Diane F.

AU - Darzentas, Nikos

AU - Belessi, Chrysoula

AU - Davi, Frederic

AU - Ghia, Paolo

AU - Rosenquist, Richard

AU - Stamatopoulos, Kostas

PY - 2015/1/29

Y1 - 2015/1/29

N2 - An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.

AB - An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2.Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.

UR - http://www.scopus.com/inward/record.url?scp=84921856679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921856679&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-09-600874

DO - 10.1182/blood-2014-09-600874

M3 - Article

C2 - 25634617

AN - SCOPUS:84921856679

SN - 0006-4971

VL - 125

SP - 856

EP - 859

JO - Blood

JF - Blood

IS - 5

ER -

Not all IGHV3-21 chronic lymphocytic leukemias are equal: Prognostic considerations

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this